TP-050 | TP-050 : Positive allosteric of GRIN2A
RATINGS:
Cellular Use: (0 reviews)

In Model Organisms: (0 reviews)
Vendors

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
GRIN2A
    • EC50:510 nM
    Positive allosteric
    up to 30 uM

    Selectivity

    In Cell Selectivity Assessment
    Potency Assay Off-Target:
    Good NMDA-subtype selectivity (Ca2+ influx assay using CHO cells): GRIN2B EC50 > 30 µM, max potenti ...
    In Vitro Selectivity Assessment
    Potency Assay Off-Target:
    Selectivity outside target family: SAFETYscan (DiscoverX, 47 targets at 10 µM): 46 target > 10 µM; P ...

    Potency
    Cellular
    In Vitro

    GRIN2A

    Mode of Action: Positive allosteric

    Structure-Activity-Relationship data available? Yes

    DOI Reference: 10.1016/j.bmc.2021.116576

    In Vivo Validations

    Rat
    Dose: 1 mg/Kg IV, 10 mg/Kg PO
    Route of delivery: Intravenous, Oral
    Systemic clearance: 235 ± 20 mL/h/Kg
    Cmax: 1908 ± 204 ng/mL
    Area Under the Curve:: 9143 ± 2638 ngˑh/mL
    Bioavailability: 21.4%
    Volume of Distribution at Steady-State: 657 ± 44 mL/Kg
    Organ of interest (O): Brain
    Target engagement assay: TP-050 demonstrated sufficient blood–brain barrier (BBB) permeability in rats with Brain to Plasma ration around 0.5 after 2 h.

    DOI Reference: 10.1016/j.bmc.2021.116576

    Negative Control Compounds

    CANSAR3880517
    Notes: TP-050n: EC50 > 30 µM (> 59 -fold); Max. potentiation at 30 µM: 150 % (Ca2+ influx assay using CHO cells)

    Chemical Information

    Molecular Formula C16H15ClF2N6O
    SMILEs Cc1cn([C@H](C)CC#N)c(=O)c2cc(Cn3nc(C(F)F)cc3Cl)nn12
    InChI InChI=1S/C16H15ClF2N6O/c1-9(3-4-20)23-7-10(2)25-13(16(23)26)5-11(21-25)8-24-14(17)6-12(22-24)15(18)19/h5-7,9,15H,3,8H2,1-2H3/t9-/m1/s1
    Molecular weight 380.10 Da
    AlogP 0.0
    HBond acceptors 7
    HBond donors --
    Atoms 41

    Expert Reviews


    No SERP comments found for TP-050

    Probe TP-050 is in the process of SERP review.

    Please continue to check back for new reviews and commentary.